Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline

AIDS

Volumn 25, Issue 2, 2011, Pages 269-271

  Rallon, Norma I ^a   Restrepo, Clara ^a   Naggie, Susanna ^b   Lopez, Mariola ^a   Del Romero, Jorge ^c   Goldstein, David ^d   McHutchison, John ^b   Soriano, Vincent ^a   Benito, Jose M ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c CENTRO SANITARIO SANDOVAL   (Spain)

^d DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28; INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; INNATE IMMUNITY; PREVALENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD;

CD4-POSITIVE T-LYMPHOCYTES; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HIV-1; HUMANS; INTERLEUKINS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RNA, VIRAL; VIRAL LOAD;

EID: 78650883762     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328341b84e     Document Type: Article

References (14)

1. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4:69-77.
2. MarcelloT, Grakoui A, Barba-Spaeth G,Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131:1887-1898.
3. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
4. Rallón NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010; 24:F23-F29.
5. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
6. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41:1100-1104.
7. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
8. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome wide association study. Gastroenterology 2010; 138:1338-1345.
9. Pantaleo G, Menzo S, Vaccarezza M, Graziosi C, Cohen OJ, Demarest JF, et al. Studies in subjects with long-term nonpro-gressive HIV infection. N Engl J Med 1995; 332:209-216.
10. Kulkarni P, Butera S, Duerr A. Resistance to HIV-1 infection: lessons learned from studies of highly exposed persistently seronegative (HEPS) individuals. AIDS Rev 2003; 5:87-103.
11. Piacentini L, Biasin M, Fenizia C, Clerici M. Genetic correlates of protection against HIV infection: the ally within. J Intern Med 2009; 265:110-124.
12. HouW,WangX,YeL, ZhouL, Yang ZQ, RiedelE, etal. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. J Virol 2009; 83:3834-3842.
13. Livak K. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 1999; 14:143-149.
14. Restrepo C, Rallón NI, del Romero J, Rodŕguez C, Hernando V, López M, et al. Low-level exposure to HIV induces virus-specific T cell responses and immune activation in exposed HIV-seronegative individuals. J Immunol 2010; 185:982-989.